GAF® (Glyoxal Acid Free) – Formalin Free Fixative



Every day in Europe, around 1,000,000 healthcare workers are exposed to carcinogenic formalin vapors, and the resulting five times higher than average risk of developing occupational diseases (respiratory tract cancer, asthma, allergies) as well as cognitive dysfunction.

Formalin, in fact, is an aqueous solution based on formaldehyde. Formaldehyde is a substance classified by the EU as carcinogenic and mutagenic (like asbestos), and its use has been strictly limited by EU Regulation ((EU) 2014/895, (EU) 2018/675, EU 2019/983).

However, in the absence of a technically viable and safe alternative, formalin is still currently the most widely used standard fixative in Pathological Anatomy, for tissue fixation. Addax Biosciences has developed, patented, and validated GAF®, an innovative histological, non-carcinogenic fixative, capable of offering the same tissue fixation performance and diagnostic accuracy, over the full range of application as formalin.



– Turin Hospital – first mover trial in 2018
– Candiolo Cancer Institute (IRCCS) – Clinical Performance Study center 2019-2022
– Manchester Cancer Institute – Clinical Performance Study center 2019-2022
– Val d’Hebron Hospital di Barcellona – Clinical Performance Study center 2019-2022
– University of Padova – Vet trial 2019-2022
– Dental School University of Turin – succesfully trialed 2021-2022

Addax Biosciences

- Visit Homepage

Addax Biosciences srl
Phone: +39 388 77 989 77
Michela Gastaldi